{"id":"NCT03242590","sponsor":"Lipocine Inc.","briefTitle":"Dosing Validation Study of Oral Testosterone Undecanoate (TU, LPCN 1021).","officialTitle":"Validation of Dosing Regimen of Oral Testosterone Undecanoate (TU, LPCN 1021) in Hypogonadal Men.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-12","primaryCompletion":"2017-03","completion":"2017-07","firstPosted":"2017-08-08","resultsPosted":"2019-09-11","lastUpdate":"2019-10-23"},"enrollment":95,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hypogonadism, Male"],"interventions":[{"type":"DRUG","name":"LPCN 1021","otherNames":[]}],"arms":[{"label":"Oral testosterone undecanoate, LPCN 1021","type":"EXPERIMENTAL"}],"summary":"Multicenter, open-label, one treatment study evaluating the efficacy of LPCN 1021 in adult hypogonadal male subjects.","primaryOutcome":{"measure":"Percent of LPCN 1021-treated Subjects Who Achieve a Total Testosterone Average Concentration [Cavg] in the Normal Range","timeFrame":"Following 24 days of treatment","effectByArm":[{"arm":"Oral Testosterone Undecanoate, LPCN 1021","deltaMin":80,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["34994093"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":95},"commonTop":["Blood prolactin increased","Blood FSH decreased","Blood LH decreased","PSA increased","Weight increased"]}}